A New Horizon in Cancer Treatment: Suppressing Steroid Production

The greatest problem in treating solid (organ) cancers is that the tumor microenvironment uses different mechanisms to stimulate tumor growth and suppress cancer drugs and the immune system.
The mechanisms cancer cells use through the tumor microenvironment include;
- immunosuppressive cells,
- activation of apoptosis in T lymphocytes,
- disruption of the antigen-presentation mechanisms needed to initiate an acquired immune response,
- secretion of immunosuppressive cytokines, and
- conversion of the type 1 immune response that prevents tumor formation into a type 2 immune response that supports tumor development.
All these mechanisms reduce the effectiveness of the treatments given to the patient.
Another condition that suppresses the immune system is the secretion of large amounts of steroid hormones. Steroidogenesis is the biological process that converts cholesterol in the body into steroids. Cholesterol in the cell cytoplasm is transferred to the mitochondria, where an enzyme called Cyp11a1 converts it into pregnenolone, a precursor compound of steroids. One study found that Th2 lymphocytes spontaneously produce steroids, helping maintain normal balance (homeostasis) by limiting the body's immune response to parasitic infections. Following this finding, another question occurred to scientists: could T lymphocytes in the tumor microenvironment also spontaneously produce steroids, suppressing the immune system and promoting tumor growth?
To answer this question, researchers used two types of mouse models: a wild-type strain capable of producing the Cyp11a1 enzyme, and a model in which the gene producing Cyp11a1 had been deleted. Analysis showed that tumor volume was much smaller in the model with the deleted gene, where Cyp11a1 was not produced. The team also used an agent that suppresses enzyme activity in wild-type mice whose enzyme-producing gene had not been deleted. Results similar to the previous experiments were obtained: significant reductions in tumor volume were detected with the inhibitory agent.
The study results provide many benefits in different areas. First, identifying the gene that triggers steroid production or the presence of steroids in patients will be extremely helpful in preparing an appropriate treatment plan. In addition, using drugs that target and suppress the activity of the Cyp11a1 enzyme will help reduce steroid levels and thereby strengthen the antitumor immune response.
All these developments will help resolve the fundamental problems related to the tumor microenvironment that limit treatment responses, particularly in solid tumors, establish the most appropriate treatment plan for individuals and improve the response to treatment.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.